-
Maxygen Announces Final Rejection of All Claims of Amgen '804 Patent in Inter Partes Reexamination Proceeding
Monday, October 10, 2011 - 5:01pm | 161Maxygen, Inc. (Nasdaq: MAXY) today announced that the United States Patent and Trademark Office (PTO) has issued a Right of Appeal Notice in the inter partes reexamination proceeding for Amgen's U.S. Pat. No. 7,381,804 that includes a final rejection of all claims in the ‘804 patent. Amgen's ‘804...
-
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn®
Monday, October 10, 2011 - 8:02am | 182Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into a global licensing agreement with Chiva Pharmaceuticals, Inc. for Fablyn (lasofoxifene), a selective estrogen receptor modulator that was approved in the EU in 2009 for the treatment of osteoporosis in post-...
-
Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
Tuesday, October 4, 2011 - 4:05pm | 134Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has achieved its second milestone in its collaboration with Abbott for elagolix and next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. The Company and Abbott held a pre- phase III meeting with the FDA, the...
-
Neurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment in Second Phase II Clinical Trial
Monday, September 19, 2011 - 4:00pm | 92Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a second Phase II clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this second Phase II study is a randomized, double-blind, placebo controlled, cross-over trial...
-
Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Tuesday, September 13, 2011 - 8:31am | 66Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids. The initiation of this trial triggered a $10 million...
-
Lexicon Pharmaceuticals Announces LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Tuesday, September 13, 2011 - 7:17am | 73Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2). The favorable safety profile and effects on multiple parameters of glycemic...
-
UPDATE: Piper Jaffray Upgrades Metabolix To Neutral
Friday, September 9, 2011 - 7:49am | 73According to Piper Jaffray, Metabolix (NASDAQ: MBLX) is upgraded to Neutral. Piper Jaffray said that it views shares of MBLX trading at just above cash levels as fairly valued and have elected to upgrade our rating to Neutral while maintaining a $5 target. “We expect the cash drag from crop...
-
Benzinga's Top Upgrades
Friday, September 9, 2011 - 7:41am | 136Analysts at Sterne Agee has upgraded Carter's Inc (NYSE: CRI) from “neutral” to “buy.” Carter's shares closed at $30.09 yesterday. Carter's PEG ratio is 1.42. Analysts at Piper Jaffray upgraded Metabolix Inc (NASDAQ: MBLX) from “underweight” to “neutral.” MBLX's shares closed at $4.93 yesterday....
-
Piper Jaffray Upgrades Metabolix To Neutral, $5 Price Target
Friday, September 9, 2011 - 6:18am | 25Piper Jaffray has upgraded Metabolix (NASDAQ: MBLX) from Underweight to Neutral and has established a $5 price target.
-
Wednesday's Biotech Stocks Trading
Thursday, September 8, 2011 - 12:27pm | 647Point Roberts, WA - September 9, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for September 07, 2011. Aethlon Medical, Inc. (OTC: AEMD) closed lower by 3.03% to $0.0640 on volume of 164K shares...
-
Maxygen Announces $10M Increase in Stock Repurchase Program
Thursday, September 8, 2011 - 8:03am | 81Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011. Since December 2009, Maxygen has...
-
Mad Money Lightning Round: Cramer Likes Ligand Pharmaceuticals
Thursday, September 8, 2011 - 3:58am | 160On CNBC's Mad Money, Jim Cramer said during the Lightning Round that PriceSmart (NASDAQ: PSMT) is a “good stock, but I'm a believer in Costco (NASDAQ: COST)." Cramer said that Sprint Nextel's (NYSE: S) “financials are too tough for me. I can't go there with the AT&T (NYSE: T) and T-Mobile...
-
MediciNova Announces CFO, CMO Appointments
Friday, September 2, 2011 - 6:58am | 36MediciNova (Nasdaq: MNOV) today announced the appointments of Kazuko Matsuda, M.D., Ph.D, MPH as Chief Medical Officer and Michael Gennaro CPA, MBA as Chief Financial Officer.
-
Rodman & Renshaw Outperform On Keryx Biopharmaceuticals
Thursday, September 1, 2011 - 1:20pm | 182Rodman & Renshaw is out with a research report on Keryx Biopharmaceuticals (NASDAQ: KERX) and it has an Outperform rating and a $8 price target on shares. In a note to clients, Rodman & Renshaw writes, "We are reiterating our Market Outperform / Speculative Risk rating and our target...
-
McNicoll, Lewis & Vlak Maintains Keryx Biopharmaceuticals Buy, $18 PT
Wednesday, August 31, 2011 - 5:04pm | 132McNicoll, Lewis & Vlak maintained its Keryx Biopharmaceuticals (NASDAQ: KERX) Buy rating and $18 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Based on positive efficacy and safety results of a small, 35-patient, randomized, double-blind...